The Food and Drug Administration (FDA) approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to reduce the risk for febrile neutropenia in patients treated with chemotherapy in certain types of cancer.
In this week’s episode of CURE Talks Cancer, we spoke with Matt Lashey, creator and CEO of the chemoWave app, which is designed to manage cancer symptoms and conditions by keeping track of a patient’s overall well-being to understand how their experiences may be related to feeling better or worse during treatment.
For those living with lymphedema, everyday life can present both challenges and dangers. Learning how to avoid injury is vitally important but with just a few precautions, you can learn to protect your affected limb.
Despite awareness that many cancer survivors suffer from treatment-related sexual dysfunction, sexual aids and resources are not readily available to them — even at leading cancer centers throughout the United States.